3026226-90-1
Chemical Structure
Pergolide-d7 mesylate
Synonym(s): Pergolide methanesulfonate-d7;LY127809-d7
- CAS No.: 3026226-90-1
- Formula:C20H23D7N2O3S2
- Molecular Weight:417.64
IUPAC Name: (1S,5S)-3-((3-hydroxy-2-phenylpropanoyl)oxy)-8-isopropyl-8-(propan-2-yl-d7)-8-azabicyclo[3.2.1]octan-8-ium bromide
InChIKey: UWCVGPLTGZWHGS-RHIUWHKTSA-N
SMILES: [H][C@@]1(N(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])C[C@H](CSC)C[C@@]12[H])CC3=CNC4=CC=CC2=C43.CS(=O)(O)=O
Biological Activity: Pergolide-d7 (mesylate) is the deuterium labeled Pergolide mesylate. Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pergolide-d7 mesylate | Pergolide-d7 (mesylate) is the deuterium labeled Pergolide mesylate. Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pergolide mesylate (Standard) | ≥98% | Pergolide (mesylate) (Standard) is the analytical standard of Pergolide (mesylate). This product is intended for research and analytical applications. Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pergolide mesylate | 99.98% | Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. S Franks, et al. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Br Med J (Clin Res Ed). 1983 Apr 9;286(6372):1177-9. [Content Brief]
